Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Clear Cell Sarcoma of the Kidney Follow-up

  • Author: Nita Seibel, MD; Chief Editor: Max J Coppes, MD, PhD, MBA  more...
 
Updated: Oct 25, 2015
 

Further Outpatient Care

After completing chemotherapy, patients should continue to have regular blood work and radiographic scans on an outpatient basis, which decreases in frequency over time. The ideal follow up schedule has not been established particularly for the length of follow up. Generally, these visits occur every 1-3 months for the first year, every 3-6 months for the second and third years, then yearly thereafter. Investigators in Europe and in North America have reported an increase in number of CNS recurrences of clear cell sarcoma of the kidney (CCSK). The brain should be routinely scanned with other areas (such as lungs).

Clear cell sarcoma of the kidney tumors are associated with late recurrence; the most common site of recurrence is the brain and then the lung. Unlike Wilms tumors, patients remain at risk for recurrence after 2 years posttherapy. Tumors may recur as long as 10 years after completion of treatment. However, with the recent treatment approaches, most recurrences occur within 3 years of the completion of therapy.

Treatment of patients with recurrent clear cell sarcoma of the kidney depends on initial therapy. Cyclophosphamide and carboplatin should be considered if not used initially. Patients with recurrent clear cell sarcoma of the kidney that involves the brain have responded to treatment with ifosfamide, carboplatin, and etoposide (ICE), coupled with local control consisting of either surgical resection and/or radiation. Patients with recurrent clear cell sarcoma of the kidney should be considered for treatment on available pediatric phase I and phase II clinical trials.[12]

Patients require follow-up evaluation in a late-effects clinic and monitoring with appropriate tests because they have a single kidney. Patients are assessed for toxic effects resulting from chemotherapy, radiotherapy, or both. Follow-up visits should include renal, psychosocial, cardiac, and hormonal evaluations.

Next

Further Inpatient Care

Pediatricians often refer patients with an abdominal mass to a pediatric general surgeon or urologist (if a known renal mass is present). These specialists should involve pediatric oncologists preoperatively. Chest CT scans should be obtained before surgery to eliminate confusion regarding areas of atelectasis that may be difficult to separate from metastases. In addition, if abnormal findings are revealed on chest CT scans, a biopsy of lung tissue can be planned at the time of surgery.

Chemotherapy may be administered on an outpatient (depending on the facilities) or inpatient basis.

Fever and neutropenia may occur, requiring hospitalization for intravenous antibiotics and monitoring.

Previous
Next

Inpatient & Outpatient Medications

Trimethoprim-sulfamethoxazole is indicated in patients who have undergone irradiation therapy to the lung. This should continue throughout the course of treatment and for 6 months posttherapy.

Previous
Next

Transfer

Although the major therapy for cancer should occur at a center staffed by pediatric oncologists, referring physicians should continue to play an important role in the child's care throughout treatment. The referring physician can be critical in performing the first evaluation of an illness, particularly if the child lives far from the oncology center.

Patients may be referred to pediatric general surgeons and urologists.

Previous
Next

Deterrence/Prevention

No preventive measures for childhood cancers currently are known.

Previous
Next

Complications

Cardiomyopathy results primarily from anthracycline (doxorubicin) use. Patients should obtain routine follow-up echocardiograms after the completion of therapy.

Patients are at risk for renal failure because they have a single kidney.

Radiation effects have decreased but, in the past, have consisted of asymmetry of the muscle mass in the back.

Secondary malignant neoplasms may arise as a result of chemotherapy (particularly alkylating agents in combination with radiotherapy).

Infertility may occur as a result of the alkylating agents.

A risk of intestinal obstruction is noted.

Previous
Next

Prognosis

Patients who have stage I tumors, are aged 2-4 years, and have no tumor necrosis tend to have a better prognosis.[13]

Patients who present with distant metastases or multifocal disease have a poor prognosis, with a 50% long-term 6-year survival rate.

Treatment with doxorubicin has resulted in a 66% reduction in the tumor-related mortality rate.

Previous
Next

Patient Education

Parents and patients must undergo formal chemotherapy instruction to learn about the adverse effects of medication. They must be encouraged to call with any questions and to become educated regarding the expectations of chemotherapy.

Parents must be taught regarding flushing schedules and how to maintain and care for the central venous catheter if it exits the skin and the procedure to follow if the patient develops a fever.

Patients who have undergone abdominal surgery are at risk for developing intestinal obstructions or scar tissue related to the surgery. Families must be educated to call when abdominal pain or vomiting develop that are not related to an infectious cause. All members of the pediatric oncology team also must have a heightened awareness of the risk of obstruction in these patients so that an abdominal radiograph is obtained if any suggestion of obstruction exists.

For excellent patient education resources, visit eMedicineHealth's Cancer Center. Also, see eMedicineHealth's patient education article Renal Cell Cancer.

Previous
 
Contributor Information and Disclosures
Author

Nita Seibel, MD Senior Investigator, Pediatric Section, Clinical Investigations Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute; Adjunct Professor of Pediatrics, George Washington University School of Medicine and Public Health; Attending Physician, Center for Cancer and Blood Disorders, Children's National Medical Center

Nita Seibel, MD is a member of the following medical societies: Alpha Omega Alpha, American Society of Clinical Oncology, American Academy of Pediatrics, American Society of Hematology

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Timothy P Cripe, MD, PhD, FAAP Chief, Division of Hematology/Oncology/BMT, Gordon Teter Endowed Chair in Pediatric Cancer, Nationwide Children's Hospital; Professor of Pediatrics, Ohio State University College of Medicine

Timothy P Cripe, MD, PhD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American Association for Cancer Research, American Pediatric Society, American Society of Gene and Cell Therapy, American Society of Pediatric Hematology/Oncology, Connective Tissue Oncology Society, Society for Pediatric Research, Children's Oncology Group

Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA Executive Vice President, Chief Medical and Academic Officer, Renown Heath

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American College of Healthcare Executives, American Society of Pediatric Hematology/Oncology, Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Kathleen M Sakamoto, MD, PhD Shelagh Galligan Professor, Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine

Kathleen M Sakamoto, MD, PhD is a member of the following medical societies: International Society for Experimental Hematology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Society for Pediatric Research

Disclosure: Nothing to disclose.

References
  1. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer. 1978 May. 41(5):1937-48. [Medline].

  2. Morgan E, Kidd JM. Undifferentiated sarcoma of the kidney: a tumor of childhood with histopathologic and clinical characteristics distinct from Wilms' tumor. Cancer. 1978 Oct. 42(4):1916-21. [Medline].

  3. Marsden HB, Lawler W, Kumar PM. Bone metastasizing renal tumor of childhood: morphological and clinical features, and differences from Wilms' tumor. Cancer. 1978 Oct. 42(4):1922-8. [Medline].

  4. Argani P, Perlman EJ, Breslow NE, et al. Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol. 2000 Jan. 24(1):4-18. [Medline].

  5. Seibel NL, Sun J, Anderson JR, et al. Outcome of clear cell sarcoma of the kidney (CCSK) treated on the National Wilms Tumor Study-5 (NWTS). [Abstract. J Clin Oncol(Supplement 18). 2006. 24:A9000.

  6. Hadley GP, Sheik-Gafoor MH. Clear cell sarcoma of the kidney in children: experience in a developing country. Pediatr Surg Int. 2010 Apr. 26(4):345-8. [Medline].

  7. Seibel NL, Li S, Breslow NE, et al. Effect of duration of treatment on treatment outcome for patients with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 2004 Feb 1. 22(3):468-73. [Medline].

  8. Lalwani N, Prasad SR, Vikram R, Katabathina V, Shanbhogue A, Restrepo C. Pediatric and adult primary sarcomas of the kidney: a cross-sectional imaging review. Acta Radiol. 2011 May 1. 52(4):448-57. [Medline].

  9. Taguchi K, Kojima Y, Mizuno K, Kamisawa H, Kohri K, Hayashi Y. Molecular analysis of clear cell sarcoma with translocation (1;6)(p32.3;q21). Urology. 2011 Sep. 78(3):684-6. [Medline].

  10. Cutcliffe C, Kersey D, Huang CC, et al. Clear cell sarcoma of kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Can Res. 2005. 11:7986-7994. [Medline]. [Full Text].

  11. Green DM, Breslow NE, Beckwith JB, et al. Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1994 Oct. 12(10):2132-7. [Medline].

  12. Gooskens SL, Furtwängler R, Spreafico F, van Tinteren H, de Kraker J, Vujanic GM, et al. Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study. Br J Cancer. 2014 Jul 15. 111 (2):227-33. [Medline]. [Full Text].

  13. Kalapurakal JA, Perlman EJ, Seibel NL, Ritchey M, Dome JS, Grundy PE. Outcomes of patients with revised stage I clear cell sarcoma of kidney treated in National Wilms Tumor Studies 1-5. Int J Radiat Oncol Biol Phys. 2013 Feb 1. 85 (2):428-31. [Medline].

  14. Amin MB, de Peralta-Venturina MN, Ro JY, et al. Clear cell sarcoma of kidney in an adolescent and in young adults: a report of four cases with ultrastructural, immunohistochemical, and DNA flow cytometric analysis. Am J Surg Pathol. 1999 Dec. 23(12):1455-63. [Medline].

  15. Balarezo FS, Joshi VV. Clear cell sarcoma of the pediatric kidney: detailed description and analysis of variant histologic patterns of a tumor with many faces. Adv Anat Pathol. 2001 Mar. 8(2):98-108. [Medline].

  16. Brownlee NA, Perkins LA, Stewart W, et al. Recurring translocation (10;17) and deletion (14q) in clear cell sarcoma of the kidney. Arch Pathol Lab Med. 2007 Mar. 131(3):446-51. [Medline].

  17. Charles AK, Vujanic GM, Berry PJ. Renal tumours of childhood. Histopathology. 1998 Apr. 32(4):293-309. [Medline].

  18. Jones C, Rodriguez-Pinilla M, Lambros M, et al. c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours. J Clin Pathol. 2007 Nov. 60(11):1226-31. [Medline].

  19. Little SE, Bax DA, Rodriguez-Pinilla M, et al. Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. Clin Cancer Res. 2007 Aug 1. 13(15 Pt 1):4360-4. [Medline].

  20. Punnett HH, Halligan GE, Zaeri N, Karmazin N. Translocation 10;17 in clear cell sarcoma of the kidney. A first report. Cancer Genet Cytogenet. 1989 Aug. 41(1):123-8. [Medline].

  21. Radulescu VC, Gerrard M, Moertel C, et al. Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis. Pediatr Blood Cancer. 2008 Feb. 50(2):246-9. [Medline].

  22. Rakheja D, Weinberg AG, Tomlinson GE, et al. Translocation (10;17)(q22;p13): a recurring translocation in clear cell sarcoma of kidney. CancerGenet Cytogenet. 2004. 154:175-9. [Medline].

  23. Sebire NJ, Vujanic GM. Paediatric renal tumours: recent developments, new entities and pathological features. Histopathology. 2008 Aug 11. [Medline].

 
Previous
Next
 
Large right-sided heterogeneous renal mass in a 9-month-old infant. Biopsy findings were consistent with clear cell sarcoma of the kidney.
Recurrent clear cell sarcoma of the kidney occurring in a lymph node 18 months after therapy.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.